ASCO26: Gastrointestinal cancers enter the limelight amid key readout surge

Readouts in hepatocellular carcinoma, as well as pancreatic, gastric and salivary gland cancer, are catching attention at ASCO 2026. Readouts in hepatocellular carcinoma, as well as pancreatic, gastric and salivary gland cancer, are capturing attention at ASCO 2026. As daraxonrasib’s pancreatic cancer win makes waves in the oncology space, other GI cancer readouts have come into the spotlight. Credit: CoreDESIGN / Shutterstock.com. With the 2026 American Society of Clinical Oncology (ASCO) conference, held in Chicago from 29 May to 2 June, in full swing, there has been a notable buzz around readouts in hard-to-treat gastrointestinal (GI) indications such as pancreatic…

Source: Clinical Trials Arena